Table 1.
Demographic characteristics of 42 spondyloarthritis patients
| Characteristic | Total (42 patients) | Without ADA (31 patients) | With ADA (11 patients) | p value |
|---|---|---|---|---|
| Sex, male | 23 (54.8%) | 16 (51.6%) | 7 (63.6%) | 0.726 |
| Age | 49.60 ± 10.46 | 51.26 ± 10.08 | 44.91 ± 10.53 | 0.084 |
| HLA-B27-positivea | 23/36 (64%) | 17/27 (63%) | 6/9 (66.7%) | 0.841 |
| Disease duration (years) | 12.24 ± 8.23 | 11.61 ± 8.04 | 14 ± 8.92 | 0.416 |
| Baseline ASDAS | 3.42 ± 1.01 | 3.52 ± 1.03 | 3.14 ± 0.95 | 0.399 |
| Concomitant treatment | ||||
| Methotrexate | 9 (21.5%) | 8 (25.8%) | 1 (9.1%) | 0.498 |
| Other DMARDs | 10 (23.8%) | 5 (16.1%) | 5 (45.4%) | 0.115 |
| Methotrexate + other | 1 (4,7%) | 2 (6.4%) | 0 (0%) | 0.599 |
| DMARDs | ||||
| Monotherapy | 21 (50%) | 16 (51.7%) | 5 (45.5%) | 0.126 |
| Corticosteroid therapy | 15 (35.7%) | 9 (29%) | 6 (50%) |
Data presented as n (%) or mean ± standard deviation. ADA, anti-drug antibodies; ASDAS, Ankylosing Spondylitis Disease Activity Score; DMARD, disease-modifying anti-rheumatic drug. an/total number (%).